动物造模 z-bio 2022-02-01 731

　　Objective: To study the effectiveness and feasibility of vaccine immune intervention with human-derived RBP-4 as the target of insulin resistance, and to provide basic research data for advancing the development of new therapies for type 2 diabetes.

　　Methods: T7 phage was used as a vector to express human RBP-4 vaccine. Type 2 diabetic mice were subcutaneously immunized. An empty vector group and an empty control group were set at the same time. After two immunizations, the humoral immunity level, fasting blood glucose and body weight were sacrificed at 20 weeks Animals undergo pathological examination.

　　Result: The RBP-4 vaccine effectively induced the production of anti-BP-4 IgG antibodies, which reached a peak at 12 weeks. At the same time, the fasting blood glucose level of the immunized group gradually decreased from the 8th week. There is a significant difference between the control group and the blank group, and the incidence of type 2 diabetes (7 mmol/L) has always been maintained. During the experiment, the type 2 diabetic mice showed no abnormalities such as curling, curling, nose scratching, cramping, and no obvious pathological changes in the heart, liver, spleen, lung, and kidney tissues. The mice in the immunized and empty carrier groups showed that BP-4 and the vaccine are safe.

　　Conclusion: RBP-4 vaccine can significantly reduce blood sugar levels in type 2 diabetic mice, which may be a new breakthrough in the treatment of insulin resistance.